THE PHARMACOKINETICS AND SAFETY OF MOMELOTINIB IN SUBJECTS WITH MODERATE OR SEVERE RENAL IMPAIRMENT.

被引：0

作者：

Xin, Y. ^{[1
]}

Collins, H. ^{[1
]}

Cheng, F. ^{[1
]}

Kwan, E. ^{[1
]}

Ramanathan, S. ^{[1
]}

Silverman, J. A. ^{[1
]}

机构：

[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PII-049

引用

页码：S87 / S88

页数：2

共 50 条

[21] Lucerastat, an iminosugar for substrate reduction therapy: pharmacokinetics, tolerability, and safety in subjects with mild, moderate, and severe renal function impairment [J].

Guerard, Nicolas ;

Zwingelstein, Christian ;

Dingemanse, Jasper .

MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) :S59-S59

[22] Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment [J].

Guerard, Nicolas ;

Zwingelstein, Christian ;

Dingemanse, Jasper .

JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (11) :1425-1431

[23] Effect of Renal Impairment on the Pharmacokinetics and Safety of Rivipansel in Subjects with Renal Impairment and in Healthy Subjects [J].

Tammara, Brinda ;

Ryan, Kelly ;

Plotka, Anna ;

Shafer, Frank E. ;

Wei, Hua ;

Readett, David ;

Fang, Annie ;

Korth-Bradley, Joan .

BLOOD, 2018, 132

[24] Pharmacokinetics of frovatriptan in patients with renal impairment. [J].

Cohen, AF ;

van der Post, J ;

Sacks, S ;

Marsh, J ;

Buchan, P .

CEPHALALGIA, 1999, 19 (04) :365-365

[25] The Pharmacokinetics of Voclosporin (VCS) in Renal Impairment. [J].

Freitag, D. ;

Huizinga, R. ;

Mayo, P. ;

Ling, S. ;

Foster, R. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 :335-335

[26] Pharmacokinetics of pioglitazone in patients with renal impairment. [J].

Edwards, G ;

Eckland, DJA .

DIABETOLOGIA, 1999, 42 :A230-A230

[27] Pharmacokinetics, Efficacy and SAFETY of Lesinurad, a Novel URAT1 Inhibitor, In Individuals with Mild to Moderate Renal Impairment. [J].

Hagerty, David ;

Kerr, Brad ;

Shen, Zangong ;

Yeh, Li-tain ;

Hingorani, Vijay ;

Cravets, Matt ;

Welp, Jody ;

Miner, Jeffrey N. ;

Manhard, Kimberly ;

Quart, Barry .

ARTHRITIS AND RHEUMATISM, 2011, 63 (10) :S402-S402

[28] SINGLE-DOSE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST APROCITENTAN IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT. [J].

Fontes, M. ;

Halabi, A. ;

Tomaszewska-Kiecana, M. ;

Dinge-Manse, J. ;

Sidharta, P. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 :S47-S48

[29] Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. [J].

Ravis, WR ;

Stokes, TJ ;

Reid, S ;

Van Ess, PJ ;

Roniker, B ;

Sica, D ;

Tolbert, D .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) :P37-P37

[30] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment [J].

J Dowell ;

E Seltzer ;

M Buckwalter ;

T Marbury ;

D Simoneau ;

E Boudry .

Critical Care, 12 (Suppl 2)

← 1 2 3 4 5 →